Abstract

Theranostics signals the integrated application of molecular diagnostics, therapeutic treatment and patient response monitoring. Such integration has hitherto neglected another crucial dimension: coproduction of theranostic scientific knowledge, novel technological development and broader sociopolitical systems whose boundaries are highly porous. Nanodiagnostics applications to theranostics are one of the most contested and potentially volatile postgenomics innovation trajectories as they build on past and current tensions and promises surrounding both nanotechnology and personalized medicine. Recent science policy research suggests that beneficial outcomes of innovations do not simply flow from the generation of scientific knowledge and technological capability in a linear or automatic fashion. Thus, attempts to offset public concerns about controversial emerging technologies by expert risk assurances can be unproductive. Anticipation provides a more robust basis for governance that supports genuine healthcare progress. This article presents a synthesis of novel policy approaches that directly inform theranostics medicine and the future(s) of postgenomics healthcare.

Original languageEnglish (US)
Pages (from-to)857-870
Number of pages14
JournalExpert Review of Molecular Diagnostics
Volume12
Issue number8
DOIs
StatePublished - Nov 2012

Fingerprint

Medicine
Delivery of Health Care
Precision Medicine
Nanotechnology
Molecular Pathology
Physiologic Monitoring
Technology
Theranostic Nanomedicine
Therapeutics
Research

Keywords

  • anticipatory governance
  • engagement
  • ethics
  • innovation policy
  • nanodiagnostics
  • nanotechnology
  • responsible innovation
  • risk and uncertainty
  • sociotechnical integration
  • theranostics medicine

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pathology and Forensic Medicine

Cite this

Responsible healthcare innovation : Anticipatory governance of nanodiagnostics for theranostics medicine. / Fisher, Erik; Boenink, Marianne; Van Der Burg, Simone; Woodbury, Neal.

In: Expert Review of Molecular Diagnostics, Vol. 12, No. 8, 11.2012, p. 857-870.

Research output: Contribution to journalArticle

@article{f8a282f13bcb4f6788308e82afcc58bc,
title = "Responsible healthcare innovation: Anticipatory governance of nanodiagnostics for theranostics medicine",
abstract = "Theranostics signals the integrated application of molecular diagnostics, therapeutic treatment and patient response monitoring. Such integration has hitherto neglected another crucial dimension: coproduction of theranostic scientific knowledge, novel technological development and broader sociopolitical systems whose boundaries are highly porous. Nanodiagnostics applications to theranostics are one of the most contested and potentially volatile postgenomics innovation trajectories as they build on past and current tensions and promises surrounding both nanotechnology and personalized medicine. Recent science policy research suggests that beneficial outcomes of innovations do not simply flow from the generation of scientific knowledge and technological capability in a linear or automatic fashion. Thus, attempts to offset public concerns about controversial emerging technologies by expert risk assurances can be unproductive. Anticipation provides a more robust basis for governance that supports genuine healthcare progress. This article presents a synthesis of novel policy approaches that directly inform theranostics medicine and the future(s) of postgenomics healthcare.",
keywords = "anticipatory governance, engagement, ethics, innovation policy, nanodiagnostics, nanotechnology, responsible innovation, risk and uncertainty, sociotechnical integration, theranostics medicine",
author = "Erik Fisher and Marianne Boenink and {Van Der Burg}, Simone and Neal Woodbury",
year = "2012",
month = "11",
doi = "10.1586/erm.12.125",
language = "English (US)",
volume = "12",
pages = "857--870",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "8",

}

TY - JOUR

T1 - Responsible healthcare innovation

T2 - Anticipatory governance of nanodiagnostics for theranostics medicine

AU - Fisher, Erik

AU - Boenink, Marianne

AU - Van Der Burg, Simone

AU - Woodbury, Neal

PY - 2012/11

Y1 - 2012/11

N2 - Theranostics signals the integrated application of molecular diagnostics, therapeutic treatment and patient response monitoring. Such integration has hitherto neglected another crucial dimension: coproduction of theranostic scientific knowledge, novel technological development and broader sociopolitical systems whose boundaries are highly porous. Nanodiagnostics applications to theranostics are one of the most contested and potentially volatile postgenomics innovation trajectories as they build on past and current tensions and promises surrounding both nanotechnology and personalized medicine. Recent science policy research suggests that beneficial outcomes of innovations do not simply flow from the generation of scientific knowledge and technological capability in a linear or automatic fashion. Thus, attempts to offset public concerns about controversial emerging technologies by expert risk assurances can be unproductive. Anticipation provides a more robust basis for governance that supports genuine healthcare progress. This article presents a synthesis of novel policy approaches that directly inform theranostics medicine and the future(s) of postgenomics healthcare.

AB - Theranostics signals the integrated application of molecular diagnostics, therapeutic treatment and patient response monitoring. Such integration has hitherto neglected another crucial dimension: coproduction of theranostic scientific knowledge, novel technological development and broader sociopolitical systems whose boundaries are highly porous. Nanodiagnostics applications to theranostics are one of the most contested and potentially volatile postgenomics innovation trajectories as they build on past and current tensions and promises surrounding both nanotechnology and personalized medicine. Recent science policy research suggests that beneficial outcomes of innovations do not simply flow from the generation of scientific knowledge and technological capability in a linear or automatic fashion. Thus, attempts to offset public concerns about controversial emerging technologies by expert risk assurances can be unproductive. Anticipation provides a more robust basis for governance that supports genuine healthcare progress. This article presents a synthesis of novel policy approaches that directly inform theranostics medicine and the future(s) of postgenomics healthcare.

KW - anticipatory governance

KW - engagement

KW - ethics

KW - innovation policy

KW - nanodiagnostics

KW - nanotechnology

KW - responsible innovation

KW - risk and uncertainty

KW - sociotechnical integration

KW - theranostics medicine

UR - http://www.scopus.com/inward/record.url?scp=84871345750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871345750&partnerID=8YFLogxK

U2 - 10.1586/erm.12.125

DO - 10.1586/erm.12.125

M3 - Article

C2 - 23249203

AN - SCOPUS:84871345750

VL - 12

SP - 857

EP - 870

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7159

IS - 8

ER -